Findings

What do systematic reviews say?

134 questions · 134 findings · 2 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 0.7%GRADE not reported 39 · 29.1%Very low 1 · 0.7%Low 5 · 3.7%Moderate 86 · 64.2%High 2 · 1.5%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Paroxetine vs older ADs · Failure to respond at endpoint (6‐12 weeks)
  Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.04 [0.92, 1.17]
  34 studies · 4647 participants
  Moderate
Direct match · question page
- Paroxetine vs reboxetine · Failure to respond at 1‐4 weeks
  Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 0.66 [0.5, 0.87]
  3 studies · 1375 participants
  Moderate
Direct match · question page
- Paroxetine vs reboxetine · Failure to respond at 16‐24 weeks
  Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
Direct match · question page
- Paroxetine vs sertraline · Failure to respond at endpoint (6‐12 weeks)
  Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.25 [0.89, 1.77]
  3 studies · 618 participants
  Moderate
Direct match · question page
- Paroxetine vs reboxetine · Failure to remit at endpoint
  Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Paroxetine vs aprepitant

Failure to respond at endpoint (6‐12 weeks) · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs aprepitant

Failure to respond at 1‐4 weeks · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs aprepitant

Failure to respond at 16‐24 weeks · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs aprepitant

Failure to remit at endpoint · patients with depression

Paroxetine leads to higher failure to remit at endpoint compared with aprepitant (high certainty).

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
OR 1.57 [1.08, 2.29]
4 studies · 807 participants
High

Paroxetine vs aprepitant

SMD at endpoint · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
High

Paroxetine vs aprepitant

Failure to complete ‐ any cause ‐ · patients with depression

Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with aprepitant (moderate certainty).

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
OR 1.53 [0.76, 3.09]
1 study · 143 participants
Moderate

Paroxetine vs aprepitant

Participants with at least some Side Effects · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs placebo

Depression symptom reduction · people with anxiety and comorbid alcohol use disorders

1 finding from 1 review

Pharmacotherapy for anxiety and comorbid alcohol use disorders 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Paroxetine vs older ADs

Failure to respond at endpoint (6‐12 weeks) · patients with depression

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with older ADs (moderate certainty).

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
OR 1.04 [0.92, 1.17]
34 studies · 4647 participants
Moderate

Paroxetine vs agomelatine

Failure to respond at 16‐24 weeks · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs reboxetine

Failure to respond at 1‐4 weeks · patients with depression

Paroxetine probably leads to lower failure to respond at 1‐4 weeks compared with reboxetine (moderate certainty).

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
OR 0.66 [0.5, 0.87]
3 studies · 1375 participants
Moderate

Paroxetine vs reboxetine

Failure to respond at 16‐24 weeks · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs reboxetine

Failure to remit at endpoint · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs reboxetine

SMD at endpoint · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1291 participants
Moderate

Paroxetine vs reboxetine

Failure to complete ‐ any cause ‐ · patients with depression

Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with reboxetine (moderate certainty).

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
OR 0.78 [0.51, 1.19]
3 studies · 1375 participants
Moderate

Paroxetine vs reboxetine

Participants with at least some Side Effects · patients with depression

Paroxetine showed no clear difference in participants with at least some Side Effects compared with reboxetine (moderate certainty).

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
OR 1.08 [0.74, 1.58]
3 studies · 1375 participants
Moderate

Paroxetine vs sertraline

Failure to respond at endpoint (6‐12 weeks) · patients with depression

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with sertraline (moderate certainty).

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
OR 1.25 [0.89, 1.77]
3 studies · 618 participants
Moderate

Paroxetine vs sertraline

Failure to respond at 1‐4 weeks · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs sertraline

Failure to respond at 16‐24 weeks · patients with depression

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Paroxetine vs sertraline

Failure to remit at endpoint · patients with depression

Paroxetine showed no clear difference in failure to remit at endpoint compared with sertraline (moderate certainty).

1 finding from 1 review

Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
OR 0.94 [0.67, 1.34]
2 studies · 545 participants
Moderate